|
1
|
Bacci G, Longhi A, Fagioli F, Briccoli A,
Versari M and Picci P: Adjuvant and neoadjuvant chemotherapy for
osteosarcoma of the extremities: 27 year experience at Rizzoli
Institute, Italy. Eur J Cancer. 41:2836–2845. 2005.PubMed/NCBI
|
|
2
|
Perry CM and Figgitt DP: Zoledronic acid:
a review of its use in patients with advanced cancer. Drugs.
64:1197–1211. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Green JR: Skeletal complications of
prostate cancer: pathophysiology and therapeutic potential of
bisphosphonates. Acta Oncol. 44:282–292. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baulch-Brown C, Molloy TJ, Yeh SL, Ma D
and Spencer A: Inhibitors of the mevalonate pathway as potential
therapeutic agents in multiple myeloma. Leuk Res. 31:341–352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iguchi K, Nakano T, Usui S and Hirano K:
Incadronate inhibits aminopeptidase N expression in prostatic PC-3
cells. Cancer Lett. 237:223–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nakajima H, Magae J, Tsuruga M, Sakaguchi
K, Fujiwara I, Mizuta M, Sawai K, Yamagishi H and Mizuta N:
Induction of mitochondria-dependent apoptosis through the
inhibition of mevalonate pathway in human breast cancer cells by
YM529, a new third generation bisphosphonate. Cancer Lett.
253:89–96. 2007. View Article : Google Scholar
|
|
7
|
Tassone P, Tagliaferri P, Viscomi C,
Palmieri C, Caraglia M, D’Alessandro A, Galea E, Goel A, Abbruzzese
A, Boland CR and Venuta S: Zoledronic acid induces
antiproliferative and apoptotic effects in human pancreatic cancer
cells in vitro. Br J Cancer. 88:1971–1978. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Im GI, Qureshi SA, Kenney J, Rubash HE and
Shanbhag AS: Osteoblast proliferation and maturation by
bisphosphonates. Biomaterials. 25:4105–4115. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Viereck V, Emons G, Lauck V, Frosch KH,
Blaschke S, Gründker C and Hofbauer LC: Bisphosphonates pamidronate
and zoledronic acid stimulate osteoprotegerin production by primary
human osteoblasts. Biochem Biophys Res Commun. 291:680–686. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wittrant Y, Théoleyre S, Chipoy C,
Padrines M, Blanchard F, Heymann D and Rédini F: RANKL/RANK/OPG:
new therapeutic targets in bone tumours and associated osteolysis.
Biochim Biophys Acta. 1704:49–57. 2004.PubMed/NCBI
|
|
11
|
Dougall WC and Chaisson M: The
RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer
Metastasis Rev. 25:541–549. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baud’huin M, Duplomb L, Ruiz Velasco C,
Fortun Y, Heymann D and Padrines M: Key roles of the OPG-RANK-RANKL
system in bone oncology. Expert Rev Anticancer Ther. 7:221–232.
2007.PubMed/NCBI
|
|
13
|
Plotkin LI, Manolagas SC and Bellido T:
Dissociation of the pro-apoptotic effects of bisphosphonates on
osteoclasts from their anti-apoptotic effects on
osteoblasts/osteocytes with novel analogs. Bone. 39:443–452. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Green JR: Antitumor effects of
bisphosphonates. Cancer. 97:840–847. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Horie N, Murata H, Nishigaki Y, Matsui T,
Segawa H, Nogawa M, Yuasa T, Kimura S, Maekawa T, Fushiki S and
Kubo T: The third-generation bisphosphonates inhibit proliferation
of murine osteosarcoma cells with induction of apoptosis. Cancer
Lett. 238:111–118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koshimune R, Aoe M, Toyooka S, Hara F,
Ouchida M, Tokumo M, Sano Y, Date H and Shimizu N: Anti-tumor
effect of bisphosphonate (YM529) on non-small cell lung cancer cell
lines. BMC Cancer. 7:82007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dickson PV, Hamner JB, Cauthen LA, Ng CY,
McCarville MB and Davidoff AM: Efficacy of zoledronate against
neuroblastoma. Surgery. 140:227–235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dunford JE, Thompson K, Coxon FP, Luckman
SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ:
Structure-activity relationships for inhibition of farnesyl
diphosphate synthase in vitro and inhibition of bone resorption in
vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther.
296:235–242. 2001.
|
|
19
|
Ishikawa C, Matsuda T, Okudaira T, Tomita
M, Kawakami H, Tanaka Y, Masuda M, Ohshiro K, Ohta T and Mori N:
Bisphosphonate incadronate inhibits growth of human T-cell
leukaemia virus type I-infected T-cell lines and primary adult
T-cell leukaemia cells by interfering with the mevalonate pathway.
Br J Haematol. 136:424–432. 2007. View Article : Google Scholar
|
|
20
|
Caraglia M, Santini D, Marra M, Vincenzi
B, Tonini G and Budillon A: Emerging anti-cancer molecular
mechanisms of aminobisphosphonates. Endocr Relat Cancer. 13:7–26.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ory B, Blanchard F, Battaglia S, Gouin F,
Rédini F and Heymann D: Zoledronic acid activates the DNA S-phase
checkpoint and induces osteosarcoma cell death characterized by
apoptosis-inducing factor and endonuclease-G translocation
independently of p53 and retinoblastoma status. Mol Pharmacol.
71:333–343. 2007. View Article : Google Scholar
|
|
22
|
Mori K, Le Goff B, Berreur M, Riet A,
Moreau A, Blanchard F, Chevalier C, Guisle-Marsollier I, Léger J,
Guicheux J, et al: Human osteosarcoma cells express functional
receptor activator of nuclear factor-kappa B. J Pathol.
211:555–562. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Benassi MS, Chiechi A, Ponticelli F,
Pazzaglia L, Gamberi G, Zanella L, Manara MC, Perego P, Ferrari S
and Picci P: Growth inhibition and sensitization to cisplatin by
zoledronic acid in osteosarcoma cells. Cancer Lett. 250:194–205.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Dai J, Qi Y, Lin DL, Smith P,
Strayhorn C, Mizokami A, Fu Z, Westman J and Keller ET:
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis
and prevents prostate tumor growth in the bone. J Clin Invest.
107:1235–1244. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ishii R, Morimoto A, Ikushima S, Sugimoto
T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J and Imashuku
S: High serum values of soluble CD154, IL-2 receptor, RANKL and
osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood
Cancer. 47:194–199. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mintz MB, Sowers R, Brown KM, Hilmer SC,
Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, et
al: An expression signature classifies chemotherapy-resistant
pediatric osteosarcoma. Cancer Res. 65:1748–1754. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grimaud E, Soubigou L, Couillaud S,
Coipeau P, Moreau A, Passuti N, Gouin F, Redini F and Heymann D:
Receptor activator of nuclear factor kappaB ligand
(RANKL)/osteoprotegerin (OPG) ratio is increased in severe
osteolysis. Am J Pathol. 163:2021–2031. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Quinn JE, Brown LG, Zhang J, Keller ET,
Vessella RL and Corey E: Comparison of Fc-osteoprotegerin and
zoledronic acid activities suggests that zoledronic acid inhibits
prostate cancer in bone by indirect mechanisms. Prostate Cancer
Prostatic Dis. 8:253–259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tannehill-Gregg SH, Levine AL, Nadella MV,
Iguchi H and Rosol TJ: The effect of zoledronic acid and
osteoprotegerin on growth of human lung cancer in the tibias of
nude mice. Clin Exp Metastasis. 23:19–31. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng Y, Zhou H, Brennan K, Blair JM,
Modzelewski JR, Seibel MJ and Dunstan CR: Inhibition of bone
resorption, rather than direct cytotoxicity, mediates the
anti-tumour actions of ibandronate and osteoprotegerin in a murine
model of breast cancer bone metastasis. Bone. 40:471–478. 2007.
View Article : Google Scholar : PubMed/NCBI
|
